Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2015 Feb;15(2):151-6. doi: 10.1586/14737140.2015.1003047. Epub 2015 Jan 14.

Current role of cabozantinib in metastatic castration-resistant prostate cancer.

Author information

1
Dana-Farber Cancer Institute, Harvard Medical School 450 Brookline Avenue (DANA 1230), Boston, MA 02215, USA.

Abstract

Over 80% of men with castration-resistant prostate cancer have bone metastases. This condition can dramatically impact quality of life and is associated with short-term survival. Consequently, the development of bone-targeted therapies is a relevant topic on prostate cancer management. Hepatocyte growth factor receptor and vascular endothelial growth factor signaling pathways have been identified to play a role in prostate cancer progression and bone metastasis and are potential targets for therapeutic intervention. Early-phase studies have shown encouraging responses in bone metastases and pain control with cabozantinib, a multi-tyrosine kinase inhibitor targeting hepatocyte growth factor receptor and vascular endothelial growth factor receptor. Despite striking responses seen in some patients, preliminary results from a pivotal Phase III study have failed to produce survival benefit. This review encompasses preclinical and clinical data of cabozantinib in metastatic castration-resistant prostate cancer highlighting future research options for this agent.

KEYWORDS:

MET; VEGF; XL-184; bone metastasis; cabozantinib; castration-resistant prostate cancer

PMID:
25586337
DOI:
10.1586/14737140.2015.1003047
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center